Abstract

Objective
The aim of our study was to evaluate the incidence, causes, risk factors, outcomes, and cost of hospital readmission after live related renal transplantation (LRRT).

Methods
We conducted a cross-sectional study and followed patients’ re-admissions for six months whose LRRT was done in our center between September 2019 and June 2020.

Results
We recruited 53 patients, 40 (75.5%) were male. The mean age was 36.9 ± 11.9 years. Donor gender was similar, and their mean age was 31.6 ± 9.2 years. The mean length of hospital stay after LRRT was 14 ± 2.2 days. A total of 81.1% were readmitted after LRRT within the first six months, with a total of 113 readmissions. The median time of readmission after LRRT was 66 days. The median readmission hospital stay was four days. The causes of readmission were surgical in 11 (9.7%), medical in 89 (78.8%), and combined medical and surgical in 13 (11.5%). Infection was the most common medical cause, followed by rejection. Statistically significant difference between readmission and non-readmission groups was found in estimated glomerular filtration rate (eGFR) at six month 61.3 ± 25.9 vs. 84.3 ± 36.1 mL/min/1.73 m² respectively (p = 0.02). The median cost of readmission was PKR 40629, equivalent to USD 261.

Conclusion
Over three-fourths of the patients were readmitted after LRRT within the first six months. The most common causes were infection and rejection. Readmissions after LRRT are associated with lower graft function at six months and a significant cost burden on the health system.

Introduction
Since the first renal transplant by Murray in 1954 [1], it is now considered the treatment of choice for patients with end-stage kidney disease (ESKD). It offers improvements in life expectancy and quality of life for most patients compared to remaining on dialysis [2-3].

Re-hospitalization after renal transplant surgery is common [4-5], because of the complexity of immunosuppression regimens, rejection, infection, and other transplant-specific complications and has been shown to have a significant impact on the health care cost, morbidity, graft loss, and death [4,6-7].

After transplantation, within the first 30 days, surgical complications related to the procedure are predominant [4, 8]. After that, immunological and infective causes tend to be more common. Early acute rejection (EAR) occurs in less than three months and late acute rejection (LAR) occurs after three months of transplant [9]. The majority of the infections are seen within 1-6 months [10] and found to be a significant problem in developing countries post-transplant [11].

Examining cause-specific re-hospitalization in these renal transplant patients may help identify possible avoidable factors that may prevent readmission. There is a lack of data about hospital readmission after kidney transplantation from developing countries. Pakistan is a developing country where more than 40% of the population live below the poverty line, transplant programs are mainly based on community-government partnerships, and local philanthropy plays a vital role [12]. Donation of organs from non-relatives is prohibited as per country law [13] in an attempt to combat organ trafficking. These cultural, social, and...
Economic difficulties result in reduced transplantation activity, with re-hospitalization further burdening these patients, particularly in patients that pay for transplants themselves.

In our study, we aimed to evaluate the incidence, causes, risk factors, outcomes, and cost of hospital readmission after live related renal transplantation (LRRT) in post-transplant patients of our centre, which to the best of our knowledge, is the first study from private-sector transplant program from Pakistan.

**Materials And Methods**

In this observational, cross-sectional study, we followed all the re-admissions of kidney recipients for six months after LRRT whose renal transplant was done at our centre between September 2019 and June 2020. We excluded multi-organ transplant patients, whose transplants were done outside our hospital and unrelated renal transplants and those who lost graft during admission for LRRT or were lost to follow up. Day-care admission for Double-J (DJ) removal was also not included. Inform consent was waived as data was collected without patient interaction. Transplant procedures were conducted using a standard surgical technique, and all patients had a Double-J stent placed.

Re-hospitalization was defined as a hospital admission that occurred for any reason after discharge from the initial transplant hospitalization. The patients were followed for age, gender, comorbidity, cause of the end-stage kidney disease (ESKD), donor age and gender, human leukocyte antigens (HLA) matching, induction therapy, maintenance immunosuppressant, graft function, other laboratory parameters at first discharge after renal transplantation, length of initial hospital stay during renal transplantation, day of initial hospital discharge after renal transplantation (weekday vs. weekend), the time interval between transplantation and admission, length of hospital stay, day of admission (weekday vs. weekend), causes of admission, outcome and admission cost.

Causes of admission were categorized broadly into surgical and medical. Medical causes were further subclassified into infection, rejection, calcineurin inhibitor (CNI) toxicity, and miscellaneous. As the admissions are possible for more than one cause, the frequencies of causes reported are more than the number of admissions. The outcomes in relation to estimated glomerular filtration rate (eGFR), graft loss, and death at six months of LRRT were compared between readmission and non-readmission groups.

The admission cost was taken as the total direct costs that the hospital charged for re-hospitalization of the patient (this included the costs of hospital stay, medications, surgical procedures, laboratory, imaging tests, and miscellaneous costs). The cost was adjusted for the inflation rates at 5% per year and converted from Pakistani rupees (PKR) to United States Dollar (USD) as of the conversion rate for the year of admission.

The data was entered and analyzed on SPSS version 21 (IBM Corp., Armonk, NY). Mean ± STD and median with interquartile range were computed for continuous variables, while the frequencies with percentages were calculated for categorical variables. Association between categorical variables was established by Chi-square test or Fisher exact test; on the other hand, independent t-test was applied for normally distributed continuous data, while Mann-Whitney U test was executed for skewed variables. Shapiro Wilk’s test checked the normality of data. A P-value of <0.05 was set as a significant level.

**Results**

We recruited 53 patients for this study, of which 40 (75.5%) were male, while females were 13 (24.5%). The mean age of patients was 36.9 ± 11.9 years. The most common comorbidity was hypertension (HTN) (50, 94.3%) in these patients, while unknown kidney disease (bilateral small shrunken kidneys) was the most prevalent cause of chronic kidney disease (CKD) (28, 52.8%). The mean CKD vintage of patients before LRRT was 4.0 ± 5.0 years, while the patients remained on hemodialysis (HD) before LRRT for 1.0 ± 1.2 years. Most patients, 44 (83%), were being dialyzed via arterio-venous fistula (AVF) at the time of LRRT.

An almost equal number of recipients received kidneys from males (49.1%) and females (50.9%) donors. Twenty-three (43.4%) were from siblings. The mean age of the donor was 31.6 ± 9.2 years. The majority of our patients had ≥3 antigen HLA match (40, 75.5%), and standard induction (with methylprednisolone) was given to most of the patients (42, 79.2%), with 49 (92.5%) were started on maintenance immunosuppressant with prednisolone, cyclosporine, and mycophenolate mofetil (MMF). The mean length of initial hospital stay after renal transplantation surgery was 14 ± 2.2 days. During the initial hospital stay after LRRT, five (9.4%) patients developed surgical complications while 51 (98.1%) suffered medical problems. One patient required hemodialysis after transplant surgery. Twenty-three (43.4%) underwent transplanted kidney biopsy, and 21 (39.6%) had renal allograft rejection episodes. The mean best creatinine achieved after LRRT was 1.27 ± 0.89 mg/dl while creatinine at discharge after LRRT surgery was 1.47 ± 1.03 mg/dl. Most of the patients, 46 (86.6%), were discharged on working days after transplant surgery. Demographic, clinical, and laboratory characteristics among LRRT patients and their comparison in readmission and non-readmission groups are presented in Table 1.

|                      | Readmission group n=43 | Non-readmission group n=10 |
|----------------------|------------------------|-----------------------------|

---

2022 Dashti et al. Cureus 14(2): e22043. DOI 10.7759/cureus.22043
| Variable                              | Total (n=53) | (81.1%) | (18.9%) | P-value |
|---------------------------------------|--------------|---------|---------|---------|
|                                       | Mean±STD     | Median  | IQR     | Mean±STD | Median  | IQR     |         |
| Age                                   | 36.9±11.9    | 36      | 19      | 36.4±12  | 34      | 20      | 0.585   |
| Duration of CKD                       | 4.0±5.0      | 2       | 4       | 4.3±5.1  | 2       | 5       | 0.292   |
| HD vintage                            | 1.0±1.2      | 0.8     | 0.7     | 1±1.3    | 0.8     | 0.7     | 0.908   |
| Donor Age                             | 31.6±9.2     | 28      | 12      | 31.8±8.8 | 29      | 11      | 0.682   |
| Hospital stay during LRRT             | 14±2.5       | 13      | 1       | 13.9±2.3 | 13      | 1       | 0.427   |
| Best Creatinine after LRRT            | 1.27±0.9     | 1       | 0.6     | 1.2±0.8  | 1       | 0.6     | 0.785   |
|                                       | 1.5±1.3      | 1       | 1.2     |
| Male                                  | 40 (75.3)    | 36 (63.7)| 4 (40) | 0.004   |
| Female                                | 13 (24.5)    | 7 (16.3) | 6 (60) |
| Comorbidty: Hypertension              | 50 (94.3)    | 40 (93) | 10 (100)| 0.615   |
| Diabetes Mellitus                     | 4 (5.7)      | 3 (7)   | 1 (10)  | 0.999   |
| Hepatitis B                           | 2 (3.8)      | 2 (4.7) | 0       | 0.999   |
| Hepatitis C                           | 5 (9.4)      | 3 (7)   | 2 (20)  | 0.235   |
| Causes of CKD: Unknown                | 28 (52.8)    | 21 (48.8)| 7 (70) |
| Diabetic kidney disease               | 1 (1.9)      | 1 (2.3) | 0       |         |
| Glomerulonephritis                    | 12 (22.6)    | 10 (23.3)| 2 (20) |
| Renal stone                           | 8 (15.1)     | 7 (16.3) | 1 (10) |
| ADPKD                                 | 4 (7.5)      | 4 (9.3) | 0       |         |
| HD-access: Arteriovenous fistula      | 43 (81.1)    | 35 (81.4)| 8 (80) |
| Temporary Catheter                    | 10 (18.9)    | 8 (18.6)| 2 (20)  | 0.919   |
| Donor Gender: Male                    | 26 (49.1)    | 23 (53.5)| 3 (30) |
| Female                                | 27 (50.9)    | 20 (46.5)| 7 (70) |
| HLA-matching: ≥3 antigen              | 40 (75.5)    | 34 (79.1)| 6 (60) |
| <3 antigen                            | 13 (24.5)    | 9 (20.9)| 4 (40)  | 0.207   |
| Induction Therapy: Methylprednisolone | 42 (79.2)    | 36 (83.7)| 6 (60) |
| Basiliximab                           | 10 (18.9)    | 7 (16.3)| 3 (30)  | 0.078   |
| Rituximab+plasmapheresis              | 1 (1.9)      | 0       | 1 (10)  |         |
| Complications of LRRT: No             | 17 (32.1)    | 14 (32.6)| 3 (30) |
| Surgical                              | 5 (9.4)      | 4 (9.3) | 1 (10)  | 0.999   |
| Medical                               | 31 (58.5)    | 25 (58.1)| 6 (60) |
| Episodes of rejection after LRRT: No  | 32 (60.4)    | 26 (60.5)| 6 (60) |
| Yes                                   | 21 (39.6)    | 17 (39.5)| 4 (40) |
| Day of discharge after LRRT: Weekend  | 48 (88.6)    | 37 (66) | 9 (80)  | 0.739   |
| Weekend                               | 7 (13.2)     | 6 (14)  | 1 (10)  |         |

**TABLE 1: Baseline characteristics among LRRT patients in readmission and non-readmission group**

LRRT: Live related renal transplantation; CKD: Chronic kidney disease; HD: Hemodialysis; ADPKD: Autosomal dominant polycystic kidney disease;
Baseline laboratory parameters are discussed in Table 2.

| Variable          | Total (n=53) | Readmission group n=43 (81.1%) | Non-readmission group n=10 (18.9%) | p-value |
|-------------------|--------------|-------------------------------|------------------------------------|---------|
|                   | Mean±STD     | Median                        | IQR                                |         |
| Creatinine        | 1.5±1        | 1.2                           | 0.7                                |         |
| Hemoglobin        | 10±1.4       | 9.8                           | 1.9                                | 0.071   |
| Leukocyte         | 11.5±5.3     | 11.1                          | 6                                  | 0.203   |
| Platelet          | 250±134      | 225                           | 93                                 | 0.733   |
| Albumin           | 2.9±0.5      | 2.9                           | 0.6                                | 0.031   |
| Sodium            | 137.5±3.8    | 137                           | 6                                  | 0.563   |
| Potassium         | 4±0.6        | 4.1                           | 0.7                                | 0.978   |
| Bicarbonate       | 21.3±3.3     | 21                            | 4                                  | 0.123   |
| Calcium           | 8.9±0.8      | 9                             | 1.2                                | 0.317   |
| Phosphorus        | 2.5±1.5      | 2.2                           | 1.1                                | 0.317   |
| Magnesium         | 1.58±0.44    | 1.5                           | 0.47                               | 0.213   |
| Alanine-aminotransferase | 21.7±23.4 | 14                            | 14                                 | 0.187   |
| Aspartate aminotransferase | 18.5±8.7 | 16                            | 11                                 | 0.432   |
| Cyclosporin level C0 | 204±105    | 181                           | 151                                | 0.345   |
| Cyclosporin level C2 | 1094±390   | 1057                          | 515                                | 0.348   |

TABLE 2: Baseline laboratory parameters at initial discharge among LRRT patients in readmission and non-readmission group

Out of 53 patients, 43 (81.1%) patients were readmitted after LRRT within the first six months, with 23 (45.4%) admitted within 30 days and 33 (62.5%) within three months. Forty-three transplanted patients resulted in a total of 113 readmissions within six months of renal transplantation. The average admission days per patient was 2.1 ± 1.89, 18 (34%) had more than two admissions. The median time of readmission after LRRT was 66 days, with 32 (28.3%) readmissions were within 30 days, 41 (36.3%) readmissions were from >30 days to three months, and 40 (35.4%) were from three months onward. Eighty-six (76.1%) admissions were made on weekdays and 27 (23.9%) on weekends. The median readmission hospital stay was four days.

There was no impact of demographic, clinical, and laboratory variables on readmission, that was statistically significant except for the patient’s gender. Males (36, 90%) were readmitted more than females (7, 53.8%) (p = 0.004), while serum albumin at initial discharge after transplant surgery was found to be better in readmission group (p = 0.03) (Table 1).

The causes of readmission were isolated surgical in 11 (9.7%), medical in 89 (78.8%), and combined medical and surgical in 13 (11.5%). Thirteen (54.2%) out of 24 surgical readmissions causes and 74.5% of readmissions due to medical causes occurred within 30 days after discharge. The most common surgical cause of admission was ureter-related complications (7, 29%) followed by lymphocele (6, 25%). Ninety-seven (95%) out of 102 admissions due to medical causes had a single medical cause, while five (4.9%) admission had multiple medical reasons. Infection was the most common medical cause and was found in 50 (49%), followed by rejection (37, 36%), miscellaneous (15, 14.7%), and CNI toxicity (6, 5.9%). The most common infective cause was urinary tract infection (UTI) found in 19 (38%). Twenty-two (59.5%) of rejection episodes were early acute rejection (EAR), while 15 (40.5%) were late acute rejection (LAR). Table 3 shows
the distribution of causes of readmission in the first six months of LRRT.

| Causes                          | n (%) |
|--------------------------------|-------|
| Surgical                       | 24 (19)|
| Ureteric related               | 07 (29)|
| Urine leak                     | 04 (3.5)|
| Ureteric obstruction           | 03 (2.7)|
| Lymphocele                     | 06 (25)|
| Wound Infection                | 03 (12.5)|
| Miscellaneous                  | 08 (33)|
| Pancreatic pseudocyst          | 02 (1.8)|
| Pancreatitis                   | 01 (0.9)|
| Paralytic ileus                | 01 (0.9)|
| Urinary retention              | 01 (0.9)|
| Perigraft hematoma             | 01 (0.9)|
| Native Kidney Nephrectomy      | 01 (0.9)|
| Hemorrhoidectomy               | 01 (0.9)|
| Medical                        | 102 (81)|
| Infection                      | 50 (49)|
| Urinary tract infection        | 19 (16.8)|
| Septicemia                     | 14 (12.4)|
| Gastroenteritis                | 09 (8.0)|
| Cytomegalovirus                | 04 (3.5)|
| BK virus                       | 01 (0.9)|
| Tuberculosis                   | 01 (0.9)|
| Unknown                        | 02 (1.8)|
| Rejection                      | 37 (36.3)|
| Early acute rejection          | 22 (19.5)|
| Late acute rejection           | 15 (13.3)|
| Calcineurin inhibitor toxicity | 06 (5.9)|
| Miscellaneous                  | 15 (14.7)|
| Volume depletion               | 10 (8.8)|
| Acute tubular necrosis         | 03 (2.7)|
| Hyperglycemia                  | 01 (0.9)|
| Anemia                         | 01 (0.9)|

**TABLE 3: All causes of hospital readmission in the first six months after LRRT**

LRRT: Live related renal transplantation

Comparing the outcomes between readmission and non-readmission groups, a statistically significant
difference was found in eGFR at six months (61.3 ± 25.9 vs. 84.3 ± 36.1 mL/min/1.73 m² respectively) (p = 0.02). When we further compared eGFR within the readmission group, those with more than two admissions were found to have decreased eGFR than those with less than or equal to two admissions (55.1 ± 26.5 vs. 65.7 ± 25.1) (p = 0.036). No statistically significant difference was found in graft loss and death between the two groups (Table 4).

| Variable       | Total (n=53) | Readmission group n=43 (81.1%) | Non-readmission group n=10 (18.9%) | p-value |
|----------------|-------------|-------------------------------|-----------------------------------|---------|
|                | Mean±STD    | Median IQR                    | Mean±STD Median IQR               |         |
| Serum creatinine | 1.7±1.4     | 1.38 0.6                      | 1.7±1.2 0.6                      | 1.1 0.7 | 0.042 |
| eGFR           | 65.6±29.1   | 63 34                         | 61.3±25.9 59 32                  | 84.3±36.1 93 39 | 0.023 |
| Graft loss     | 4 (7.5%)    | 3 (7%)                        | 1 (10)                           |         | 0.744 |
| Death          | 2 (3.8%)    | 2 (4.7%)                      | 0                                 |         | 0.487 |

**TABLE 4: Outcome between readmission and non-readmission groups at six months of LRRT**

LRRT: Live related renal transplantation; eGFR: Estimated glomerular filtration rate; IQR: Interquartile range.

The overall graft survival rate of our LRRT patients was 92.5% at six months, with 93% in the readmission group and 90% in the non-readmission group. Overall, the patient survival rate was 96% at six months, with 95% in readmission and 100% in the non-readmission group. The mean cost of readmission was PKR 61542 ± 62086 (Median 40629), equivalent to USD 396 ± 402 (Median 261, @ 1 USD = 155.6).

**Discussion**

Economic constraints, with insufficient health spending and cultural and societal hurdles in Pakistan, resulted in lower transplantation activity [11]. Re-hospitalization after transplant further burdens these patients with a significant impact on the health care cost, morbidity, graft loss, and death [4, 6-7]. There is a lack of data on the incidence, causes, risk factors, outcomes, and cost of hospital readmission after kidney transplantation (KT) from developing countries. Our study aimed to fill that gap and get insight into the quality measurement of live-related renal transplants at our centre. This is the first study from the private-sector transplant program in Pakistan.

In our study, 81.1% of patients were readmitted after LRRT within the first six months, with 43.4% admitted within 30 days and 62.5% within three months. A study from China [14] showed a readmission rate of 22.59% within one year after KT while data from the United States Renal Data System (USRDS) showed 31% (range from 18% to 47% among different transplant centres) of recipients readmitted within 30 days of discharge after KT [8]. A study from Canada [15] found early readmission rates of 19.4% at 30 days and 26.8% at 90 days post-transplant. Our high readmission rate is surprising and demands comprehensive adjudication between potentially avoidable factors, the process of care, and unpredictable acceptable risk due to the uniquely vulnerable nature of transplant procedure in the face of limited resource setup. A high re-admissions rate at our centre needs to be further evaluated.

The overall graft survival rate of our LRRT patients was 92.5% at six months, with 93% in the readmission group and 90% in the non-readmission group. Overall, the patient survival rate was 96% at six months, with 95% in readmission and 100% in the non-readmission group. The mean cost of readmission was PKR 61542 ± 62086 (Median 40629), equivalent to USD 396 ± 402 (Median 261, @ 1 USD = 155.6).

**Discussion**

Economic constraints, with insufficient health spending and cultural and societal hurdles in Pakistan, resulted in lower transplantation activity [11]. Re-hospitalization after transplant further burdens these patients with a significant impact on the health care cost, morbidity, graft loss, and death [4, 6-7]. There is a lack of data on the incidence, causes, risk factors, outcomes, and cost of hospital readmission after kidney transplantation (KT) from developing countries. Our study aimed to fill that gap and get insight into the quality measurement of live-related renal transplants at our centre. This is the first study from the private-sector transplant program in Pakistan.

In our study, 81.1% of patients were readmitted after LRRT within the first six months, with 43.4% admitted within 30 days and 62.5% within three months. A study from China [14] showed a readmission rate of 22.59% within one year after KT while data from the United States Renal Data System (USRDS) showed 31% (range from 18% to 47% among different transplant centres) of recipients readmitted within 30 days of discharge after KT [8]. A study from Canada [15] found early readmission rates of 19.4% at 30 days and 26.8% at 90 days post-transplant. Our high readmission rate is surprising and demands comprehensive adjudication between potentially avoidable factors, the process of care, and unpredictable acceptable risk due to the uniquely vulnerable nature of transplant procedure in the face of limited resource setup. A high re-admissions rate at our centre needs to be further evaluated.

The causes of readmission were found to be multifactorial. The most common causes were infection and rejection. Infection was found in 44% of overall admissions within six months. The proportion of readmissions attributable to infections was equally distributed within 30 days, >30 to three months, and three months onward. Our readmission rate is much higher than the infection-related readmissions found in the United States Renal Data System (12%) [8] and Canada (21% within 30 days and 28.1% within 90 days) [15]. However, it is similar to the findings of studies from Iran (51% and 49.6%) [5, 16]. The tendency of increased infectious events after transplant has been attributed to the use of immunosuppressive drugs, exposure to nosocomial pathogens, and the need for invasive intravascular and urinary devices.

The common infection found in our study was UTI, which correlates with studies from Canada [15], Iran [16], and Colombia [17]. In addition, a study from our centre found that 33% of renal transplant recipients had at least one episode of urinary tract infection, and the structural abnormalities, renal stone disease, delay in removing Foley’s catheter, and increased post-transplant hospital stay are risk factors leading to UTI in renal transplant recipients [18].

In contrast to the studies from Pakistan [19] and India [20], which showed 12-20% incidence of tuberculosis in developing countries, we found tuberculosis in only one patient. Moreover, in our centre, none of the transplant recipients received isoniazid prophylaxis. Since tuberculosis incidence was found higher after two years of transplantation period [19], explaining the absence of frequent tuberculosis in the early post-
in our study.

Rejection episodes in our study were early acute rejection (EAR) in 59.5% while 40.5% were late acute rejection (LAR). Rejection has also been found to be a common reason for readmission in several other studies of post-transplant early hospital readmissions [5, 15].

The overall incidence of surgical complications was low within the six months after LRRT, which correlates with the study from Famure et al. [15]. However, a majority (54.2%) occurred within 30 days, similar to what is reported by McAdams et al. [8]. A study from Iran found surgical complications as the most frequent reason for readmission within the first six months [5].

When we compared outcomes between readmission and non-readmission groups, a statistically significant (p = 0.02) difference was found in eGFR at six months. When we further compared eGFR within the readmission group, there was a statistically significant (p = 0.036) reduction in eGFR with those with multiple readmissions. McAdams et al. [7] found that patients readmitted within 30 days of transplant discharge were more likely to experience kidney allograft failure and mortality. Luan et al. [6] found that only patients readmitted to the hospital two or more times experienced higher rates of death or graft failure. In a study by Harhay et al. [23], early hospital readmission was associated with an increased risk of mortality but not all-cause graft loss. Overall graft and patient survival rate of our LRRT patients was 92.5% and 96% at six months, respectively. Another single-centre study from Pakistan found one-year graft survival of 92% and one-year patient survival of 94% [11].

The mean cost of readmission was PKR 61,542 ± 62,086 (Median 40,629) equivalent to USD 396 ± 402 (Median 261, @ 1 USD = 155.6). This cost is lower compared to hospitalization charges during the first six months mentioned in a study from Iran (709 ± 366 USD). However, it is still a matter of concern for the country where 33% of people live below the poverty line with only $1 a day for sustenance [11].

Our study was a single-centre study with a small sample size. Despite this, our study serves as baseline data for future studies on this subject, especially in this part of the world. High incidence of readmission rate after LRRT with its significant effect on graft function and health care cost demands understanding and prevention of potentially avoidable factors and measures to improve quality of care. Studies that examined the potentially avoidable hospital readmission after transplant found variable results. Harhay et al. [22] found that only 9% of early readmissions were preventable, while Goldfield et al. [23] found that 21% are preventable.

In contrast to developed countries, developing countries like Pakistan confront economic limitations and essential public health fundamentals such as clean water, sanitation, and vaccination. It also faces the technical challenges of surgery, increased rate of infections, and limited medical, surgical, and nursing work forces with the required expertise. These factors probably give a higher rate of preventable readmission in our patients if the study identifies potentially avoidable factors in this cohort. If a sufficient number of hospital re-admissions are preventable, interventions may be designed and tested to decrease the burden of re-admissions.

The limitation of the study is that the sample size was small, so for these types of studies, we need larger prospective studies in collaboration with different institutes.

Conclusions

In our study, over three-fourths of the patients were readmitted after LRRT within the first six months. This
rate of readmissions is higher than studies from developed countries. The causes of readmission were found to be multifactorial. The most common causes were infection and rejection. There has been substantial variability in the specific risk factors identified in various studies. However, we did not find any statistically significant association between already identified significant factors from literature in our study, except for males that were readmitted more than females. Readmissions after LRRT are associated with lower graft function at six months and a significant cost burden on the health system.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. The Kidney Centre Ethical Review Committee issued approval 84-NEPH-02019. Your submission Reference No. 84-NEPH-02019(EXEMPTION), titled: ‘Re-hospitalization in first six months after live related renal transplantation: Risk factors, burden, causes, and outcomes’, has been given exemption by TKC-ERC. You may proceed with your study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We would like to extend our gratitude towards Dr. Bina Salman for her help with the statistics portion of this paper.

References

1. Murray JE, Reid DE, Harrison JH, Merrill JP: Successful pregnancies after human renal transplantation. N Engl J Med. 1963, 269:341-345. 10.1056/NEJM196308152690704
2. Wolfe RA, Ashby VB, Milford EL, et al.: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999, 341:1725-1730. 10.1056/NEJM19991230341005
3. Schaubel DE, Wei G, Dykstra DM, Port FK, Merion RM: Hospitalization patterns before and after liver transplantation. Transplantation. 2007, 84:1590-1594. 10.1097/TP.0b013e318034d2d5
4. Li AH, Lam NN, Naylor KL, Garg AX, Knoll GA, Kim SJ: Early hospital readmissions after transplantation: burden, causes, and consequences. Transplantation. 2016, 100:715-718. 10.1097/TP.0000000000001917
5. Lankarani M, Noorbalah M, Assari S: Causes of re-hospitalization in different post kidney transplantation periods. Ann Transplant. 2009, 14:14-19.
6. Luan FL, Barrantes F, Roth RS, Samaniego M: Early hospital readmissions post-kidney transplantation are associated with inferior clinical outcomes. Clin Transplant. 2014, 28:487-495. 10.1111/trc.12347
7. McAdams-Demarco MA, Grams ME, King E, Desai NM, Segev DL: Sequelae of early hospital readmission after kidney transplantation. Am J Transplant. 2014, 14:397-403. 10.1111/aft.12563
8. McAdams-Demarco MA, Grams ME, Hall EC, Coresh J, Segev DL: Early hospital readmission after kidney transplantation: patient and center-level associations. Am J Transplant. 2012, 12:5285-5288. 10.1111/j.1600-6143.2012.04285.x
9. Jalalzadeh M, Moussavinashab N, Peyrovi S, Ghadiani MH: The impact of acute rejection in kidney transplantation on long-term allograft and patient outcome. Nephr-Urol Mon. 2015, 7:e24459. 10.5812/nemonthly.24459
10. Kazmojigu H, Harman R, Mercimek MN, Dokur M, Uysal E: Evaluation of early and late-term infections after renal transplantation: clinical experiences of Sanko University Medical Faculty Transplantation Center. Turk J Urol. 2019, 45:63-69. 10.5152%2Ftud.2018.09522
11. Rizvi SA, Naqvi SA, Hussain Z, et al.: Renal transplantation in developing countries. Kidney Int Suppl. 2003, 63:96-100. 10.1046/j.1523-1755.63.s83.20.x
12. Rizvi SA, Naqvi SA, Zafar MN: Renal transplantation in Pakistan. Clin Transpl. 2002, 1:191-200.
13. The transplantation of human organs and tissues act 2010. (2010). http://punjablaws.gov.pk/laws/2428a.html
14. Chu A, Zhang T, Fang Y, Yuan L, Guan X, Zhang H: Unplanned hospital readmissions after kidney transplantation among patients in Hefei, China: incidence, causes and risk factors. Int J Nurs Sci. 2020, 7:291-296. 10.1016/j.jns.2020.05.002
15. Famure O, Kim ED, Au M, et al.: What are the burden, causes, and costs of early hospital readmissions after kidney transplantation?. Prog Transplant. 2021, 31:160-167. 10.1177%2F15269428211003563
16. Bahrami A, Shams SF, EidiGahi ES, Lotfi Z, Shakeri S: Infectious complications in renal allograft recipients in the first year after transplant. Exp Clin Transplant. 2017, 15:651-635. 10.6002/ect.2016.0068
17. Giraldo-Ramírez S, Diaz-Portilla OE, Miranda-Arboleda AF, Henao-Sierra J, Echeverri-Toro LM, Jaimes F: Urinary tract infection leading to hospital admission during the first year after kidney transplantation: a retrospective cohort study. Transplant Rep. 2016, 1:18-22. 10.1016/j.trp.2016.09.001
18. Iqbal T, Naqvi R, Akhter SF: Frequency of urinary tract infection in renal transplant recipients and effect on graft function. J Pak Med Assoc. 2010, 60:826-829.
19. Akhtar S, Naseem A, Dodani S, Naqvi R, Ahmad E, Naqvi A, Rizvi A: Tuberculosis in renal transplant
recipients on isoniazid prophylaxis. Eur Respir J. 2016, 48:PA2104. 10.1183/13993003.congress-2016

20. John GT, Shankar V, Abraham AM, Mukundan U, Thomas PP, Jacob CK: Risk factors for post-transplant tuberculosis. Kidney Int. 2001, 60:1148-1153. 10.1046/j.1523-1755.2001.0600031148.x

21. Taber DJ, Palanisamy AP, Srinivas TR, et al.: Inclusion of dynamic clinical data improves the predictive performance of a 30-day readmission risk model in kidney transplantation. Transplantation. 2015, 99:324-330. 10.1097/TP.0000000000000565

22. Harhay M, Lin E, Pai A, et al.: Early rehospitalization after kidney transplantation: assessing preventability and prognosis. Am J Transplant. 2013, 13:5164-5172. 10.1111/ajt.12513

23. Goldfield NI, McCullough EC, Hughes JS, Tang AM, Eastman B, Rawlins LK, Averill RF: Identifying potentially preventable readmissions. Health Care Financ Rev. 2008, 30:75-91.